Relationship between Polymorphism of MTHFR and Curative Effect of Adjuvant Chemotherapy in Postoperative Colorectal Cancer Patients
- Author:
Ya-Ting ZHU
1
Author Information
- Publication Type:Journal Article
- Keywords: Capecitabine oxaliplatin; Colorectal cancer; Methylene tetrahydrofolate reductase; Polymorphism
- From: Chinese Pharmaceutical Journal 2017;52(18):1644-1648
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To investigate the association between methylene tetrahydrofolate reductase (MTHFR)C677T polymorphism and the efficacy of the adjuvant chemotherapy with XELOX regimen for patients who had underwent radical resection of colorectal cancer. METHODS: Sixty-two patients who had received chemotherapy with XELOX regimen following radical resection of colorectal cancer were tested for MTHFR C677T polymorphism using Kompetitive Allele-Specific PCR to analyze the association of MTHFR C677T polymorphism with the prognosis and adverse reactions to chemotherapy. RESULTS: Among the 62 patients with colorectal cancer, there were 3 allelotypes (C/C, C/T and T/T)at the MTHFR C677T locus, and their frequencies were 46.8%, 40.3%, and 12.9%, respectively. The recurrence free survival time was prolonged in C/T and T/T group than C/C group(Log-rank=4.778, P<0.05). Specifically, the relapse rate was 58.6% in patients with C/C allelotype, which was significantly higher than 33.3% in patients with T/T and C/T allelotype(Log-rank=3.985, P<0.05). TNM stage(HR=5.326, P<0.05) and MTHFR C677T polymorphism(HR=0.284, P<0.05) were shown to be the prognostic factors for postoperative adjuvant chemotherapy. The toxicities of chemotherapy were primarily gastrointestinal reactions and bone marrow suppression, without statistically significant differences across different allelotypes (P>0.05). CONCLUSION: MTHFR C677T polymorphism is associated with the prognosis with adjuvant chemotherapy with XELOX regimen, and is not associated with the toxicities of chemotherapy. TNM stage IV is predicative of worse prognosis with postoperative adjuvant chemotherapy.
